Salmon et al. used MALDI‐TOF‐MS to test the serum of 13 patients with pre‐NSCLC treated with gefitinib or erlotinib, and an EGFR‐TKI efficacy model with 8 characteristic peaks was established. Here, EGFR is linked to non-small cell lung carcinoma.